SCHEMBL407135

SCHEMBL407135

Fc1[c]c(F)cc(Cl)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22342295 0.89 TSHR (0.35)
SCHEMBL261753 0.85
SCHEMBL145305 0.81
SCHEMBL149391 0.81
SCHEMBL2348023 0.81
SCHEMBL2342604 0.75 AHR (0.33)
SCHEMBL19953076 0.73 AHR (0.50)
SCHEMBL15352881 0.72 CYP1A2 (0.32)
SCHEMBL9060576 0.72
SCHEMBL57470 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-08-01 US claimed
EP-3625222-B1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2021-07-21 EP claimed
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2021-05-20 US claimed
EP-3665156-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2020-06-17 EP claimed
US-20200179383-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2020-06-11 US claimed
CN-111094233-A Compounds, compositions and methods 戴纳立制药公司 2020-05-01 CN claimed
EP-3625222-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2020-03-25 EP claimed
CN-110612296-A Phenyl derivatives as PGE2 receptor modulators 爱杜西亚药品有限公司 2019-12-24 CN claimed
CN-110382493-A THIADIAZOLE DERIVATIVES AS PESTICIDES 拜耳农作物科学股份公司 2019-10-25 CN claimed
CN-110300522-A For preventing and treating the composition that harmful microbe includes 1- (Phenoxy-pyridin base) -2- (1,2,4- triazol-1-yl)-alcohol derivative 拜耳公司 2019-10-01 CN claimed
CN-1387527-A Quinazoline derivatives as VEGF inhibitors ASTRAZENECA AB (SE) 2002-12-25 CN claimed
EP-1244647-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS AstraZeneca AB (SE) 2002-10-02 EP claimed
US-6448264-B2 ANTIPROLIFERATIVE, -CARCINOGENIC AGENTS, ANTIINFLAMMATORY AND -ARTHRITIS AGENTS; NEURODEGENERATIVE DISEASES, E.G., ALZHEIMER'S DISEASE; CARDIOVASCULAR DISORDERS; VIRICIDES; FUNGICIDES BRISTOL-MYERS SQUIBB COMPANY 2002-09-10 US claimed
US-20020002178-A1 Use of 5-thio-, sulfinyl- and sulfonylpyrazolo[3,4-b]- pyridines as cyclin dependent kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2002-01-03 US claimed
WO-2001081348-A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-11-01 WO claimed
WO-2001032651-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ASTRAZENECA AB (SE) 2001-05-10 WO claimed
EP-1043998-A1 USE OF PYRAZOLO 3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-10-18 EP claimed
US-6107305-A Use of pyrazolo [3,4-b] pyridine as cyclin dependent kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2000-08-22 US claimed
WO-1999030710-A1 USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-06-24 WO claimed
WO-1997010220-A1 URACIL DERIVATIVE BAYER AKTIENGESELLSCHAFT (DE) 1997-03-20 WO claimed